Skip to main content
Premium Trial:

Request an Annual Quote

U of Michigan, Tempus Collaborate on Pancreatic Cancer Sequencing

NEW YORK (GenomeWeb) – The University of Michigan and Tempus have announced a collaboration on pancreatic cancer.

Under the terms of the deal, Chicago-based Tempus will provide genomic and gene expression sequencing and analysis to identify treatment opportunities for pancreatic cancer patients at Michigan's comprehensive cancer center.

Pancreatic cancer patients "do not yet have access to a host of targeted therapies with proven effectiveness in the same way that other diseases have, in part because there isn't enough patient, treatment, and outcome data to identify patterns that might lead to actionable treatments," Tempus CEO Eric Lefkofsky said in a statement. Tempus added that the disease has a five-year survival rate of 9 percent.

The deal adds to Tempus' roster of academic medical center clients. The firm has also partnered with University Hospitals Seidman Cancer Center, Rush University Medical Center, the University of Pennsylvania Abramson Cancer Center, and the Mayo Clinic.

Financial and other terms of the arrangement were not disclosed.